Coherus Oncology is entering a period with multiple important clinical trial results expected for its cancer drugs tagmokitug and casdozokitug in the second half of 2026 and first half of 2027. Previous clinical data on anti-CCR8 treatments suggest potential effectiveness in colorectal and gastric cancers, enhancing the company's growth potential. While revenues from Loqtorzi (toripalimab) are projected to rise, upcoming Q2 2026 results and possible capital raises remain risks to watch. Additionally, Coherus's toripalimab is involved in trials by other companies, offering further opportunities for positive data in the future.
The latest episode of Troutman Amin, LLP's Deserve to Win Podcast features interviews with CEOs from Contact Center Compliance, PureCaller ID, and Sonera, discussing the merger of CCC and PCID into Sonera and its impact on telecom industry consolidat...
Pepeto's crypto presale is rapidly selling out, raising over $10.398 million despite a challenging market, signaling strong investor interest. This surge coincides with Solana's price recovery to $81 and optimistic forecasts of $500 in 2026, highligh...
James Altucher projects that Elon Musk's humanoid robot, dubbed "A.R.M.," could surpass Amazon's $600 billion annual revenue by producing up to 10 million units yearly. Priced between $20,000 and $30,000 each, initial production of 1 million robots c...
Roblox has reduced its guided bookings forecast by as much as 18% and withdrawn its full-year financial outlook. This adjustment is linked to a deliberate change in the platform's algorithm, which has impacted user engagement and revenue projections....
James Altucher, a tech investor, argues Tesla is no longer just a car company but has pivoted to focus on artificial intelligence and robotics. He highlights Tesla's new project called 'A.R.M.,' an AI-powered humanoid robot, which Elon Musk envisions...
